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Biventricular Assist Device 
Terminates Polymorphic 
Ventricular Tachycardia
in Giant Cell Myocarditis
We present the case of a 55-year-old woman with giant cell myocarditis who experienced 
a rapid deterioration in her condition. As her heart failure progressed, she developed more 
ventricular ectopic beats, which culminated in a polymorphic ventricular tachycardia that 
did not improve despite immunosuppressive and antiarrhythmic therapy. Emergent biven-
tricular assist device placement, however, did eliminate her arrhythmia. (Tex Heart Inst J 
2012;39(5):719-21)
G iant cell myocarditis (GCM) is a rare form of cardiomyopathy with a high mortality rate. In the largest GCM series published to date (63 patients),1 the rate of death or cardiac transplantation was 89%, with a median sur-
vival of 5.5 months from the onset of symptoms to the time of death or transplan-
tation. Patients with GCM manifest a diffuse, infiltrative disease process and often 
have conduction system abnormalities such as heart block, bundle branch block, and 
ventricular tachycardia (VT). We present the case of a patient, diagnosed with GCM, 
whose ventricular arrhythmias were refractory to medical management but resolved 
after mechanical circulatory support.
Case Report
In 2011, a previously healthy 55-year-old Caucasian woman came to her primary care 
provider with progressive shortness of breath and abdominal fullness. A chest radio-
graph revealed pulmonary edema, and she was admitted to her local hospital. Her tro-
ponin I level was elevated, at 3.62 µg/L. An electrocardiogram revealed sinus rhythm 
with an intraventricular conduction delay resembling a left bundle branch block (Fig. 
1). Cardiac catheterization showed normal coronary arteries. An echocardiogram re-
vealed severe left ventricular systolic dysfunction (ejection fraction, 0.25), moderate-
ly decreased right ventricular function, and moderate-to-severe mitral regurgitation. 
She was treated with furosemide and nesiritide drips. Carvedilol and ramipril were 
also initiated. Her systolic blood pressure readings were between 70 and 90 mmHg, 
which made it difficult to accomplish diuresis and afterload reduction.
 She was transferred to a tertiary care facility for further management. In the 
subsequent days, her troponin levels remained elevated and she developed runs of 
asymp tomatic nonsustained VT. Her β-blocker and angiotensin-converting enzyme 
inhibitor were stopped due to hypotension, a Swan-Ganz catheter was placed, and 
milrinone and amiodarone drips were initiated. On a dosage of 0.1 µg/kg/min of mil-
rinone, she had a Fick cardiac index of 1.4 L/min/m2, a pulmonary artery diastolic 
pressure of 30 mmHg, and a mixed venous oxygen saturation (SvO2) of 46%.
 Evaluation of her cardiomyopathy included thyroid function tests, serum and urine 
protein electrophoresis, an iron panel, and a general viral serology panel, all of which 
yielded results within normal limits. Her antinuclear antibody test was positive at 
1:80, which prompted additional consideration of an autoimmune origin. Cardiac 
magnetic resonance imaging was ordered to evaluate for an infiltrative process, but 
she was not able to lie flat for the time required to complete the examination. The pa-
tient was sent for cardiac biopsy, which subsequently provided the diagnosis of giant 
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 Immunosuppressive therapy was initiated with meth-
ylprednisolone and cyclosporine. Several hours later, she 
experienced multiple episodes of VT, with rates ranging 
from 100 to 170 beats/min. An amiodarone infusion 
was re-initiated (after having been discontinued when 
her previous run of ventricular ectopic beats had sub-
sided). By the next morning, the patient was in poly-
morphic VT (Fig. 3), with a rate of approximately 140 
beats/min. The tachycardia alternated between right 
and left axis and had varying forms of right bundle 
branch morphology. This rhythm was hemodynamical-
ly tolerated: she was alert and communicating through-
out the episodes, which lasted several minutes before 
abating and then recurring. Even though her milrinone 
was increased to 0.4 µg/kg/min, her SvO2 was 40%.
 The patient was emergently transported to the cardiac 
catheterization laboratory for placement of an intra- aortic 
balloon pump, which decreased, but did not eliminate, 
her ventricular ectopic arrhythmia. She was subsequent-
ly sent for emergent placement of a CentriMag® Blood 
Pump (Thoratec Corporation; Pleasanton, Calif ) as a 
right and left ventricular assist device. After placement 
of the CentriMag, she had no further episodes of poly-
morphic VT. She achieved hemodynamic stability and 
was placed on the cardiac transplantation list. Unfortu-
nately, after 19 days of successful ventricular assist device 
support, she suffered a hemorrhagic stroke and care was 
subsequently withdrawn.
Discussion
Arrhythmias are common in heart failure, but VT in 
giant cell myocarditis is highly unusual, because it is rel-
atively slow (155 beats/min on average, in a series of 5 
patients) and does not necessarily result in hemodynam-
ic compromise.2 Although left ventricular function is 
moderately to severely depressed, the left ventricle might 
be only mildly enlarged, which reflects the rapid course 
and limited time for remodeling in this aggressive dis-
ease process.3 In a series of 9 patients with GCM,2 5 
presented with sustained monomorphic VT and the re-
maining 4 experienced monomorphic VT during their 
hospitalization.
 Our patient’s case is unusual in that she experienced 
polymorphic VT in addition to the monomorphic VT 
that is more commonly seen in GCM patients. Al-
though the mechanism for polymorphic VT has not 
been specif ically explained, the underlying myocar-
dial f ibrosis might result in multiple foci of triggered 
automaticity and early after-depolarization.4 In mono-
morphic tachycardia, it has been suggested that the 
increased fibrosis and separated myocardial strands ob-
served in histologic samples of inflammatory heart dis-
ease might provide the substrate for the unidirectional 
block and reentry that sustains the arrhythmia.5
 Our patient is also unusual in that her polymorphic 
VT was refractory to immunosuppressive and antiar-
rhythmic therapy but did resolve once biventricular 
mechanical circulatory support was initiated. We con-
sidered the addition of procainamide to the amioda-
rone, but dual antiarrhythmic therapy was rejected due 
to our concern about worsening the conduction abnor-
malities with multiple levels of blockade. Although ven-
tricular assist device support often provides increased 
Fig. 1  The initial electrocardiogram reveals sinus rhythm, left-
axis deviation, and a wide QRS that manifests an intraventricular 
conduction delay with the pattern of a left bundle branch block.
Fig. 2  Photomicrograph at myocardial biopsy reveals multinucle-
ated giant cells and myocytic necrosis consistent with giant cell 
myocarditis.
Fig. 3  Despite immunosuppressive and antiarrhythmic therapy, 
this electrocardiogram shows nonsustained polymorphic ven-
tricular tachycardia, with a rate of approximately 140 beats/min.
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hemodynamic stability, it does not routinely eliminate 
the occurrence of ventricular arrhythmias. In a series 
of 195 patients with left ventricular assist devices,6 36 
had ventricular arrhythmias after implantation. In our 
patient, the mechanical off-loading of her right and left 
ventricles might have decreased wall stress, resulting in 
a decrease in triggered activity that originated from an 
underlying lymphocytic inflammatory infiltrate.
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